Good MorningThe equities market got another shot of anti-viral medication on Thursday when Jerome Powell announced major changes in how the Federal Reserve views inflation. Instead of taking inflation at face value, the committee will use an average-inflation approach in an effort to help sustain economic growth. Under the new policy, inflation could run well above the 2.0% target before any policy action or business-stifling rate increases would be taken.
The Fed changes are intended to sustain and accelerate economic growth in the U.S. and the markets responded favorably. The Dow Jones Industrial Average led the days advance with a gain near 1.0% to set a new high for 2020. The S&P 500 and NASDAQ Composite posted smaller advances but both set new highs as well. Investors should expect to see more new highs so long as the data remains favorable.
Featured: Elon Musk's Next Big AI Project Could Open This Month (Ad) 
|
Communication Services | |
The superhero streaming wars is heating up between Walt Disney’s (NYSE: DIS) Marvel Cinematic Universe (MCU) versus AT&T’s Warnermedia’s (NYSE: T) DC Extended Universe (DCEU). For those not familiar with superhero universes, Marvel Studios broke the mold along with all box of... Read the Full Story |
|
From Our Partners | | Jeff Brown, founder and CEO of Brownstone Research, says he has uncovered what he calls one of the biggest discoveries of his career tied to the ongoing AI boom.
Brown is pointing to a key date, October 20, and is highlighting five AI-related opportunities outside the traditional stock market that most investors have never heard of. | | Click here to see the full research before October 20 |
|
Consumer Discretionary | |
Sometimes, it’s easy to overcomplicate things when it comes to investing. The truth is that many of the best investments begin with a simple thesis that anyone could understand. For example, buying shares of a company that operates a growing e-commerce business in the country with the larges... Read the Full Story |
|
Consumer Discretionary | |
It’s always good to find a bargain. And it’s especially good to make a dollar stretch further in uncertain economic times like these. That formula is working for Ollie’s Bargain Outlet (NASDAQ:OLLI). And investors will find out how well the discount chain is doing when they repor... Read the Full Story |
|
From Our Partners | | Jeff Brown, the former tech executive who picked Nvidia in 2016 before it surged as high as 37,800 percent, just got inside Elon Musk's new Cybercab, a vehicle with no steering wheel or pedals.
In 2018, the New York Post called Musk a total fraud. Brown's latest footage shows just how far that technology has come since then. | | Watch the Cybercab footage and judge Elon Musk's technology yourself |
|
Technology | |
It might be hard to reconcile how a large number of analysts are expecting a stock's price to fall, substantially, yet at the same time be worth buying, but sometimes, that's exactly the case. That's just what's going on with Qorvo (NASDAQ:QRVO), which is turning in big expectations in pretty much... Read the Full Story |
|
Consumer Staples | | One sector that has been a big winner throughout the novel coronavirus pandemic has been the discount retail sector. The discount retail sector is a $95 billion sector. Names like Walmart (NYSE:WMT) and Target (NYSE:TGT) are among the first to come to mind when consumers think low prices. But they a... Read the Full Story |
|
From Our Partners | | Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracking a new Elon Musk project he calls the most epic AI initiative in history.
The plan could give Musk access to 50 times more computing power than the rest of the world combined, a development Brown says is drawing attention from executives at Amazon, Microsoft, and Google.
Brown compares the scale of this project to the SpaceX IPO, which minted thousands of millionaires overnight. | | Click here to see the full details on Musk's next big move |
|
Markets | |
Hormel Is A Post-Pandemic Winner And Highly Valued
There are many reasons why Hormel Foods (NYSE:HRL) stock has done so well during the pandemic. To start, the company is a blue-chip consumer staple with a long history of steady, even returns. In times of trouble, those kinds of stocks are among ... Read the Full Story |
|
Consumer Discretionary | | Outdoor travel and camping retailer Camping World Holdings, Inc. (NYSE: CWH) shares have been on a rollercoaster ride after sinking to lows of $3.40 during the pandemic panic selling that shaved the benchmark S&P 500 index (NYSEARCA: SPY) by (-34%) in the five weeks ending March 24th. However, s... Read the Full Story |
|
Markets | | The healthcare industry sees trillions of dollars spent annually by people around the globe and continues to grow at a rapid pace. With so many people in need of companies that provide healthcare services, investing in stocks that play a key role in the healthcare system could certainly pay off in a... Read the Full Story |
|
Markets | | Some of the biggest moves in the market happen on earnings releases. But growth isn’t always enough to send shares higher. Even beating consensus estimates is sometimes not enough to boost the stock price.
The key is expectations – particularly, the “whisper numbers.” The wh... Read the Full Story |
|
Markets | |
At a quick glance, there’s not a lot to like about Children’s Place (NYSE:PLCE) stock. The company had to shutter its brick-and-mortar operations in response to the Covid-19 pandemic. And the stock is down nearly 200% for the year. Recent analyst ratings have not helped the business ca... Read the Full Story |
|
The Early Bird Stock Of The Day Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. | | View Today's Stock Pick |
|
